Assess whether related-party sales should be backed out of valuation (fda282)

SITUATION A health-system acquiring a specialty practice cannot treat a peg set at a seasonal high as incidental context on regulatory-approval critical-path calendar. Carve-out separation lead must close related-party sales should be from that extract under M&A Due Diligence / People and Contracts.

DECISION Carve-out separation lead in a health-system acquiring a specialty practice must choose Proceed / Reprice / Walk / Hold using regulatory-approval critical-path calendar after a peg set at a seasonal high.

HYPOTHESES TO TEST 1. The population in regulatory-approval critical-path calendar is the one a peg set at a seasonal high named, so Proceed follows for this People and Contracts file. 2. The population in regulatory-approval critical-path calendar is adjacent only to a peg set at a seasonal high; Reprice is the honest M&A Due Diligence call. 3. A health-system acquiring a specialty practice already contained a peg set at a seasonal high before regulatory-approval critical-path calendar arrived; no new People and Contracts path. 4. Provenance on regulatory-approval critical-path calendar after a peg set at a seasonal high is broken; do not pick Proceed or Reprice yet.

ANALYSIS REQUIRED 1. Name the document carve-out separation lead still needs before signing. 2. Test whether a peg set at a seasonal high is a diligence gap, a price chip, or a walk-away. 3. Separate a one-off add-back from a recurring earnings issue in regulatory-approval critical-path calendar. 4. For this M&A Due Diligence People and Contracts file, read regulatory-approval critical-path calendar against a peg set at a seasonal high and write the one fact that would move related-party sales should be for carve-out separation lead.

RECOMMENDATION Choose Proceed / Reprice / Walk / Hold on this M&A Due Diligence / People and Contracts packet (regulatory-approval critical-path calendar after a peg set at a seasonal high). The follow-on People and Contracts action is what carve-out separation lead does next: implement the option, assign an owner, and log the missing fact.

COMMAND RETURNS - Bottom-line M&A Due Diligence option on related-party sales should be, then the evidence in regulatory-approval critical-path calendar, then the action for carve-out separation lead - Hypothesis scorecard against regulatory-approval critical-path calendar: supported / rejected / untestable - Regulatory or exam hook People and Contracts would cite - People and Contracts finding in regulatory-approval critical-path calendar that a second reviewer can re-perform